Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 1/2017

Open Access 01-12-2017 | Research article

The role of α1- and α2-adrenoceptor subtypes in the vasopressor responses induced by dihydroergotamine in ritanserin-pretreated pithed rats

Authors: Eduardo Rivera-Mancilla, Victor H. Avilés-Rosas, Guadalupe Manrique-Maldonado, Alain H. Altamirano-Espinoza, Belinda Villanueva-Castillo, Antoinette MaassenVanDenBrink, Carlos M. Villalón

Published in: The Journal of Headache and Pain | Issue 1/2017

Login to get access

Abstract

Background

Dihydroergotamine (DHE) is an acute antimigraine agent that displays affinity for dopamine D2-like receptors, serotonin 5-HT1/2 receptors and α1/α2-adrenoceptors. Since activation of vascular α1/α2-adrenoceptors results in systemic vasopressor responses, the purpose of this study was to investigate the specific role of α1- and α2-adrenoceptors mediating DHE-induced vasopressor responses using several antagonists for these receptors.

Methods

For this purpose, 135 male Wistar rats were pithed and divided into 35 control and 100 pretreated i.v. with ritanserin (100 μg/kg; to exclude the 5-HT2 receptor-mediated systemic vasoconstriction). Then, the vasopressor responses to i.v. DHE (1–3100 μg/kg, given cumulatively) were determined after i.v. administration of some α1/α2-adrenoceptor antagonists.

Results

In control animals (without ritanserin pretreatment), the vasopressor responses to DHE were: (i) unaffected after prazosin (α1; 30 μg/kg); (ii) slightly, but significantly, blocked after rauwolscine (α2; 300 μg/kg); and (iii) markedly blocked after prazosin (30 μg/kg) plus rauwolscine (300 μg/kg). In contrast, after pretreatment with ritanserin, the vasopressor responses to DHE were: (i) attenuated after prazosin (α1; 10 and 30 μg/kg) or rauwolscine (α2; 100 and 300 μg/kg); (ii) markedly blocked after prazosin (30 μg/kg) plus rauwolscine (300 μg/kg); (iii) attenuated after 5-methylurapidil (α1A; 30–100 μg/kg), L-765,314 (α1B; 100 μg/kg), BMY 7378 (α1D; 30–100 μg/kg), BRL44408 (α2A; 100–300 μg/kg), imiloxan (α2B; 1000–3000 μg/kg) or JP-1302 (α2C; 1000 μg/kg); and (iv) unaffected after the corresponding vehicles (1 ml/kg).

Conclusion

These results suggest that the DHE-induced vasopressor responses in ritanserin-pretreated pithed rats are mediated by α1- (probably α1A, α1B and α1D) and α2- (probably α2A, α2B and α2C) adrenoceptors. These findings could shed light on the pharmacological profile of the vascular side effects (i.e. systemic vasoconstriction) produced by DHE and may lead to the development of more selective antimigraine drugs devoid vascular side effects.
Literature
1.
Silberstein SD, McCrory DC (2003) Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache 43:144–166CrossRefPubMed
2.
Villalón CM, Centurión D, Valdivia LF et al (2003) Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol 1:71–84CrossRefPubMed
3.
Stewart J, Tepper MD (2013) Orally inhaled dihydroergotamine: a review. Headache 2:43–53
4.
Tfelt-Hansen P (2014) Is orally inhaled dihydroergotamine (DHE) equivalent in efficacy in migraine to intravenous DHE? Headache 54:383CrossRefPubMed
5.
Silberstein SD, Kori SH (2013) Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine. CNS Drugs 27:385–394CrossRefPubMed
6.
Roquebert J, Grenié B (1986) α2-adrenergic agonist and α1-adrenergic antagonist activity of ergotamine and dihydroergotamine in rats. Arch Int Pharmacodyn 284:30–37PubMed
7.
Leysen JE, Gommeren W, Heylen L et al (1996) Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hidroxytryptamine1Dα, human 5-hidroxytryptamine1Dβ, and calf 5-hidroxytryptamine1D receptors investigated with [3H]-5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol 50:1567–1580PubMed
8.
Villalón CM, Centurión D (2007) Cardiovascular responses produced by 5-hydroxytriptamine: a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedeberg's Arch Pharmacol 376:45–63CrossRef
9.
Millan MJ, Newman-Tancredi A, Auinot V et al (2000) Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse 35:79–95CrossRefPubMed
10.
Villamil-Hernández MT, Alcántara-Vázquez O, Sánchez-López A et al (2013) Pharmacological identification of α1- and α2-adrenoceptor subtypes involved in the vasopresor responses induced by ergotamine in pithed rats. Eur J Pharmacol 715:262–269CrossRefPubMed
11.
Valdivia LF, Centurión D, Perusquía M et al (2004) Pharmacological analysis of the mechanisms involved in the tachycardic and vasopressor responses to the antimigraine agent, isometheptene, in pithed rats. Life Sci 74:3223–3234CrossRefPubMed
12.
Labastida-Ramírez A, Rubio-Beltrán E, Hernández-Abreu O et al (2017) Pharmacological analysis of the increases in heart rate and diastolic blood pressure produced by (S)-isometheptene and (R)-isometheptene in pithed rats. J Headache Pain 18:52
13.
Villamil-Hernández MT, Alcántara-Vázquez O, Sánchez-López A et al (2012) Pharmacological identification of the α2-adrenoceptor subtypes mediating the vasopressor responses to B-HT 933 in pithed rats. Eur J Pharmacol 691:118–124
14.
Bonhaus DW, Bach C, DeSouza A et al (1995) The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br J Pharmacol 115:622–628CrossRefPubMedPubMedCentral
15.
Centurión D, Sánchez-López A, Gupta S et al (2006) Potential vascular α1-adrenoceptor blocking properties of an array of 5-HT receptor ligands in the rat. Eur J Pharmacol 535:234–242CrossRefPubMed
16.
Centurión D, Ortiz MI, Saxena PR et al (2002) The atypical 5-HT2 receptors mediating tachycardia in pithed rats: pharmacological correlation with the 5-HT2A receptor subtype. Br J Pharmacol 135:1531–1539CrossRefPubMedPubMedCentral
17.
Altamirano-Espinoza AH, González-Hernández A, Manrique-Maldonado G et al (2013) The role of dopamine D2, but not D3 or D4, receptor subtypes, in quinpirole-induced inhibition of the cardioaccelerator sympathetic outflow in pithed rats. Br J Pharmacol 170:1102–1111CrossRefPubMedPubMedCentral
18.
Kleinman LI, Radford EP (1964) Ventilation standards for small mammals. J Appl Physiol 19:360–362PubMed
19.
Curtis MJ, Bond RA, Spina D et al (2015) Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172:3461–3471
20.
Steel RGD, Torrie JH (1980) Principles and Procedures of Statistics: a Biomedical Approach, 2nd edn. Tokyo, McGraw-Hill, Kogakusha Ltd
21.
Kaneta S, Kashiwabara T, Tanaka Y et al (1994) Cardiovascular effects of KRN2391, nitroglycerin and cromakalim in dihydroergotamine-treated pithed rats. Gen Pharmacol 25:963–968CrossRefPubMed
22.
Leysen JE (1985) Serotonergic binding sites. In: Vanhoutte PM (ed) Serotonin and the cardiovascular system. Raven Press, New York, pp 43–62
23.
Müller-Schweinitzer E (1984) Pharmacological actions of the main metabolites of dihydroergotamine. Eur J Clin Pharmacol 26:699–705CrossRefPubMed
24.
MaassenVanDenBrink A, Reekers M, Bax WA et al (1998) Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 98:25–30CrossRefPubMed
25.
Guimarães S, Moura D (2001) Vascular adrenoceptors: an update. Pharmacol Rev 53:319–356PubMed
26.
Müller-Schweinitzer E (1974) Studies on the peripheral mode of action of dihydroergotamine in human and canine veins. Eur J Pharmacol 27:231–237CrossRefPubMed
27.
Willems EW, Valdivia LF, Saxena PR et al (2001) The role of several α1- and α2-adrenoceptor subtypes mediating vasoconstriction in the canine external carotid circulation. Br J Pharmacol 132:1292–1298CrossRefPubMedPubMedCentral
28.
Zhou L, Vargas HM (1996) Vascular alpha 1D-adrenoceptors have a role in the pressor response to phenylephrine in the pithed rat. Eur J Pharmacol 305:173–176CrossRefPubMed
29.
Daly CJ, Deighan C, McGee A, et al (2002) A knockout approach indicates a minor vasoconstrictor role for vascular alpha1B-adrenoceptors in mouse. Physiol Genomics 9:85-91
30.
Gavin K, Docherty JR (1996) Investigation of the subtype of α2-adrenoceptor mediating pressor responses in the pithed rat. Eur J Pharmacol 318:81–87CrossRefPubMed
31.
Yoshiki H, Uwada J, Anisuzzaman AS et al (2014) Pharmacologically distinct phenotypes of α1B -adrenoceptors: variation in binding and functional affinities for antagonists. Br J Pharmacol 171:4890–4901CrossRefPubMedPubMedCentral
32.
Gupta S, Villalón CM (2010) The relevance of preclinical research models for the development of antimigraine drugs: focus on 5-HT(1B/1D) and CGRP receptors. Pharmacol Ther 128:170–190CrossRefPubMed
33.
34.
Linstra KM, Ibrahimi K, Terwiindt GM et al (2017) Migraine and cardiovascular disease in women. Maturitas 97:28–31CrossRefPubMed
35.
Chan KY, Vermeersch S, de Hoon J et al (2011) Potential mechanism of prospective antimigraine drugs: a focus on vascular (side) effects. Pharmacol Ther 129:332–351CrossRefPubMed
36.
MaassenVanDenBrink A, Meijer J, Villalón CM et al (2016) Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci 37:779–788CrossRefPubMed
37.
Korstanje C, Sprenkels R, Doods HN et al (1986) Characterization of flufylline, fluprofylline, ritanserin, butanserin and R 56413 with respect to in vivo alpha1-, alpha2- and 5-HT2-receptor antagonism and in vitro affinity for alpha1-, alpha2- and 5-HT2-receptor: comparison with ketanserin. J Pharrm Pharmacol 38:374–379CrossRef
38.
Buccioni M, Kandhavelu M, Angeli P et al (2009) Identification of α1-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens. Eur J Pharmacol 602:388–394CrossRefPubMed
39.
Hieble JP, Ruffolo RR Jr (1996) Subclassification and nomenclature of alpha 1- and alpha 2-adrenoceptors. Prog Drug Res 47:81–130PubMed
40.
Patane MA, Scott AL, Broten TP et al (1998) 4-Amino-2-4-[1-(benzyloxycarbonyl)-2(S)-[[(1,1dimethylethyl)amino]carbo-nyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765,314): A potent and selective alpha1b adrenergic receptor antagonist. J Med Chem 41:1205–1208CrossRefPubMed
41.
Goetz AS, King HK, Ward SD et al (1995) BMY 7378 is a selective antagonist of the D subtype of α1-adrenoceptors. Eur J Pharmacol 272:R5–R6CrossRefPubMed
42.
Young P, Berge J, Chapman H et al (1989) Novel α2-adrenoceptor antagonist show selectivity for α2A- and α2B-adrenoceptor subtypes. Eur J Pharmacol 168:381–386CrossRefPubMed
43.
Sporkova A, Pérez-Rivera A, Galligan JJ (2010) Interaction between α1- and α2-adrenoceptors contributes to enhanced constrictor effects of norepinephrine in mesenteric veins compared to arteries. Eur J Pharmacol 643:239–246CrossRefPubMedPubMedCentral
44.
45.
Devedjian JC, Esclapez F, Denis-Pouxviel C et al (1994) Further characterization of human α2-adrenoeptor subtypes: [3H]RX821002 binding and definition of additional selective drugs. Eur J Pharmacol 252:43–49CrossRefPubMed
46.
Sallinen J, Höglund I, Engström M et al (2007) Pharmacological characterization and CNS effects of a novel highly selective α2C-adrenoceptor antagonist JP-1302. Br J Pharmacol 150:391–402CrossRefPubMedPubMedCentral
47.
Michel MC, Hanft G, Gross G (1994) Functional studies on α1-adrenoceptor subtypes mediating inotropic effects in rat right ventricle. Br J Pharmacol 111:539–546CrossRefPubMedPubMedCentral
48.
Uhlén S, Porter AC, Neubig RR (1994) The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. J Pharmacol Exp Ther 271:1558–1565PubMed
49.
McCafferty GP, Naselsky DP, Hieble JP (1999) Characterization of postjunctional α-adrenoceptors in the pithed mouse. Gen Pharmacol 33:99–105CrossRefPubMed
50.
Görnemann T, Jähnichen S, Schurad B et al (2008) Pharmacological properties of a wide array of ergolines at functional α1-adrenoceptor subtypes. Naunyn Schmiedeberg's Arch Pharmacol 376:321–330CrossRef
Metadata
Title
The role of α1- and α2-adrenoceptor subtypes in the vasopressor responses induced by dihydroergotamine in ritanserin-pretreated pithed rats
Authors
Eduardo Rivera-Mancilla
Victor H. Avilés-Rosas
Guadalupe Manrique-Maldonado
Alain H. Altamirano-Espinoza
Belinda Villanueva-Castillo
Antoinette MaassenVanDenBrink
Carlos M. Villalón
Publication date
01-12-2017
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2017
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-017-0812-4

Other articles of this Issue 1/2017

The Journal of Headache and Pain 1/2017 Go to the issue

Research article

Excitability of the motor cortex in patients with migraine changes with the time elapsed from the last attack

Research article

A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine

Research article

Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design

Research article

The course of headache in patients with moderate-to-severe headache due to mild traumatic brain injury: a retrospective cross-sectional study

Research article

Depression and anxiety behaviour in a rat model of chronic migraine

Research article

Anodal transcranial direct current stimulation over the left temporal pole restores normal visual evoked potential habituation in interictal migraineurs